TransOral gains $40M in financing

TransOral Pharmaceuticals has closed a $40 million Series D financing. Investors included New Enterprise Associates--a new investor--as well as New Leaf Venture Partners, Montreux Equity Partners, InterWest Partners, Hamilton BioVentures, Vivo Ventures and Peninsula Equity Partners. The funding will be used to develop the company's insomnia drug Intermezzo. TransOral expects to file an NDA with the FDA in the second half of 2008.

"We believe Intermezzo will address an important and underserved segment of the insomnia market," said Jake Nunn, New Enterprise Associates Partner. "This investment provides TransOral with the financial strength to file the Intermezzo NDA and we look forward to working with the company to leverage its unique position and create significant shareholder value."

- see the company's release for details

ALSO: Canada's PainCeptor Pharma has raised $24.4 M in a series B investment round. Release

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.